Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot etc. |
| Sample | BC tissues, cell lines (MDA-MB-231, MDA-MB-468, SK-BR-3, MDA-MB-435, T47D, MCF-7, MCF-10A) |
| Expression Pattern | down-regulated |
| Function Description | To achieve cognition into the biological functions of PVT1 on breast cancer, PVT1 expression was downregulated by transfecting PVT1 siRNA into the MCF-7 and MDA-MB-231 cells, employing the scramble siRNA as a negative control.PVT1 DNA in serum and found that circulating PVT1 DNA significantly increased in the serum of breast cancer patients. circulating PVT1 DNA fragments may be a convenient means to predict the prognosis of breast cancer patients.The results demonstrated that breast cancer patients with high PVT1 expression showed significant shorter 5-year overall survival (OS) compared with patients with low PVT1 expression. |
| Pubmed ID | 28534994 |
| Year | 2017 |
| Title | Amplification and the clinical significance of circulating cell-free DNA of PVT1 in breast cancer. |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |